{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:14:47Z","timestamp":1792034087718,"version":"4.4.0"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,8,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      This open-label, nonrandomized, dose-escalation and -expansion study included 44 patients with previously treated, recurrent, platinum-resistant grade 2\/3 ovarian cancer. Treatment was intravenous navicixizumab (3 mg\/kg or 4 mg\/kg once every 2 weeks) plus paclitaxel (80 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      intravenously on days 0, 7, and 14 of 28-day cycles). The primary and secondary objectives were to evaluate the safety and efficacy of navicixizumab plus paclitaxel. An RNA-based diagnostic panel was retrospectively used to test the hypothesis that tumors with high angiogenesis or immune-suppressed tumor microenvironment (TME) subtypes (biomarker-positive) are more likely to respond to navicixizumab than those with immune-active\/-desert TME subtypes (biomarker-negative). RNA expression was analyzed in available pretreatment tumor tissue to classify 33 patients' TME subtypes, and TME panel findings were correlated with tumor response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The dose-escalation cohorts enrolled patients at navicixizumab doses of 3 mg\/kg once every 2 weeks (n = 3) and 4 mg\/kg once every 2 weeks (n = 2); 3 mg\/kg was selected for expansion (n = 39). No dose-limiting toxicities occurred. The most common grade 3\/4 treatment-related adverse events were hypertension (40.9%), neutropenia (6.8%), and thrombocytopenia (4.5%). Pulmonary hypertension occurred in 18.2% (grade 1-2). The overall objective response rate was 43.2% (95% CI, 28.3 to 59.0): 33.3% (95% CI, 17.3 to 52.8) in patients previously treated with bevacizumab, 64.3% (95% CI, 35.1 to 87.2) in bevacizumab-naive patients, and 62% (95% CI, 31.6 to 86.1) in biomarker-positive patients. The median duration of response was 6 months (95% CI, 5.4 months to not estimable).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.21.01801","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T16:00:27Z","timestamp":1650384027000},"page":"2568-2577","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":43,"title":["Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"],"prefix":"10.1200","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-0419","authenticated-orcid":false,"given":"Siqing","family":"Fu","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley R.","family":"Corr","sequence":"additional","affiliation":[{"name":"University of Colorado Hospital, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Culm-Merdek","sequence":"additional","affiliation":[{"name":"OncXerna Therapeutics Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Mockbee","sequence":"additional","affiliation":[{"name":"OncXerna Therapeutics Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Youssoufian","sequence":"additional","affiliation":[{"name":"OncXerna Therapeutics Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stagg","sequence":"additional","affiliation":[{"name":"OncoMed Pharmaceuticals Inc, Redwood City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-165X","authenticated-orcid":false,"given":"R. Wendel","family":"Naumann","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6156-8885","authenticated-orcid":false,"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-4048","authenticated-orcid":false,"given":"Rafael D.","family":"Rosengarten","sequence":"additional","affiliation":[{"name":"Genialis Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Benjamin","sequence":"additional","affiliation":[{"name":"OncXerna Therapeutics Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-0336","authenticated-orcid":false,"given":"Erika Paige","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN"},{"name":"Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN"},{"name":"Stephenson Cancer Center at the University of Oklahoma Health Sciences, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0007"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00194"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0308-5"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1038\/nature05355"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.06.005"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-15-C164"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2797"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0665-y"},{"key":"b14","first-page":"A155","volume":"8","author":"Strand-Tibbitts K","year":"2020","journal-title":"J Immunother Can"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0022"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"b17","volume-title":"Center for Drug Evaluation and Research, et al: Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection: Guidance for industry","author":"U.S. Department of Health and Human Services, Food and Drug Administration"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0061"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156403"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.01801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T18:00:45Z","timestamp":1659722445000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.01801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":19,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,8,10]]}},"alternative-id":["10.1200\/JCO.21.01801"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.01801","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742012436.793595852","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"2021-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}